Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 9;16(4):727–733. doi: 10.4103/1673-5374.296418

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2021 Neural Regeneration Research

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

PMC Copyright notice

Apoptotic protein expression in the hippocampal neurovascular unit, detected by western blot assay.

Simulated diabetes-related depression conditions resulted in the significant upregulation of caspase-3 and caspase-9 expression in the hippocampal NVU compared with control conditions. The upregulation of caspase-3 and caspase-9 was reversed by both RU-486 and LY341495 treatment compared with the untreated model. However, dexamethasone and LY379268 aggravated the upregulation of these two proteins. Data are expressed as the mean ± SD (n = 3). **P < 0.01, vs. control group. #P < 0.05, ##P < 0.01, vs. model group (G&P) (one-way analysis of variance followed by Dunnett’s post hoc test). A–F: Control, model (glucose and corticosterone, i.e., simulated diabetes-related depression conditions), RU-486 (glucocorticoid receptor blocker), dexamethasone, (glucocorticoid receptor agonist), LY341495 (mGluR_2/3 receptor blocker), and LY379268 (mGluR_2/3 receptor agonist). mGluR_2/3: metabotropic glutamate receptor 2/3.